Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Vanlev

Executive Summary

Omapatrilat OCTAVE hypertension study analysis is expected in late summer or early fall, Bristol says, following company's decision to maintain blinding until all patients have completed the 24 weeks of treatment. In July, the company projected that the data would be available for analysis by late in the second quarter (1"The Pink Sheet" July 31, 2000, p. 21)

You may also be interested in...



Bristol Vanlev OCTAVE Trial Will Compare Angioedema To ACE Inhibitors

Bristol's effort to resurrect the Vanlev NDA via the 25,000-patient OCTAVE trial will produce "the best look at angioedema for ACE inhibitors that has ever been compiled," Bristol VP-Corporate Development for the Worldwide Medicines Group Andrew Bodnar, MD, told a July 20 quarterly earnings conference call.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

UsernamePublicRestriction

Register

PS037853

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel